Zydus Lifesciences advanced 3.89% to Rs 1,137.20 after the drug maker received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil tablets.
Subscribe To Our Free Newsletter |
Zydus Lifesciences advanced 3.89% to Rs 1,137.20 after the drug maker received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil tablets.
Subscribe To Our Free Newsletter |
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!